CA2903698C - Mice expressing a limited immunoglobulin light chain repertoire - Google Patents
Mice expressing a limited immunoglobulin light chain repertoire Download PDFInfo
- Publication number
- CA2903698C CA2903698C CA2903698A CA2903698A CA2903698C CA 2903698 C CA2903698 C CA 2903698C CA 2903698 A CA2903698 A CA 2903698A CA 2903698 A CA2903698 A CA 2903698A CA 2903698 C CA2903698 C CA 2903698C
- Authority
- CA
- Canada
- Prior art keywords
- human
- mouse
- light chain
- immunoglobulin
- gene segments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/798,455 | 2013-03-13 | ||
| US13/798,455 US9796788B2 (en) | 2010-02-08 | 2013-03-13 | Mice expressing a limited immunoglobulin light chain repertoire |
| PCT/US2014/026040 WO2014160202A1 (en) | 2013-03-13 | 2014-03-13 | Mice expressing a limited immunoglobulin light chain repertoire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2903698A1 CA2903698A1 (en) | 2014-10-02 |
| CA2903698C true CA2903698C (en) | 2023-02-28 |
Family
ID=50483561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2903698A Active CA2903698C (en) | 2013-03-13 | 2014-03-13 | Mice expressing a limited immunoglobulin light chain repertoire |
Country Status (26)
| Country | Link |
|---|---|
| EP (4) | EP3501272B1 (https=) |
| JP (4) | JP6529957B2 (https=) |
| KR (2) | KR102424756B1 (https=) |
| CN (2) | CN105188357B (https=) |
| AU (3) | AU2014244020B2 (https=) |
| BR (1) | BR112015022034B1 (https=) |
| CA (1) | CA2903698C (https=) |
| CY (1) | CY1121545T1 (https=) |
| DK (2) | DK2967013T3 (https=) |
| ES (3) | ES2712207T3 (https=) |
| FI (1) | FI3501272T3 (https=) |
| HR (2) | HRP20230490T1 (https=) |
| HU (2) | HUE061977T2 (https=) |
| IL (2) | IL240563B (https=) |
| LT (2) | LT2967013T (https=) |
| MX (3) | MX391010B (https=) |
| PL (2) | PL3501272T3 (https=) |
| PT (2) | PT2967013T (https=) |
| RS (2) | RS64185B1 (https=) |
| RU (1) | RU2689664C2 (https=) |
| SG (2) | SG10201801101QA (https=) |
| SI (2) | SI3501272T1 (https=) |
| SM (2) | SMT201900196T1 (https=) |
| TR (1) | TR201901668T4 (https=) |
| WO (1) | WO2014160202A1 (https=) |
| ZA (2) | ZA201505835B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| RS59728B1 (sr) | 2011-08-05 | 2020-02-28 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lanca |
| KR20160098514A (ko) | 2011-10-17 | 2016-08-18 | 리제너론 파아마슈티컬스, 인크. | 제한된 면역글로불린 중쇄 마우스 |
| PT3597037T (pt) | 2012-06-12 | 2021-06-01 | Regeneron Pharma | Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito |
| EP2840892B1 (en) * | 2013-02-20 | 2018-04-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| KR102276752B1 (ko) | 2014-03-21 | 2021-07-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| AU2017206785C1 (en) | 2016-01-13 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
| MY199789A (en) * | 2017-09-29 | 2023-11-23 | Regeneron Pharma | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| WO2020132557A1 (en) * | 2018-12-21 | 2020-06-25 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
| EP3927832A4 (en) | 2019-02-18 | 2022-11-30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS |
| JP2022520819A (ja) | 2019-02-22 | 2022-04-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20230018439A (ko) | 2020-06-02 | 2023-02-07 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물 |
| TW202242114A (zh) | 2020-12-23 | 2022-11-01 | 美商再生元醫藥公司 | 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法 |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| CN114736927A (zh) * | 2022-05-19 | 2022-07-12 | 东北大学 | 一种单抗克隆与表达载体的构建及应用 |
| TW202430641A (zh) * | 2023-01-18 | 2024-08-01 | 美商基利科學股份有限公司 | 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途 |
| WO2026019824A1 (en) * | 2024-07-16 | 2026-01-22 | Gilead Sciences, Inc. | Human immunoglobulin common light chain transgene constructs and uses thereof |
| CN121628915A (zh) * | 2024-08-29 | 2026-03-10 | 上海泰槿生物技术有限公司 | 产生限制的免疫球蛋白轻链库的细胞、动物和方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1644417B1 (en) * | 2003-07-15 | 2014-04-30 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
| AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| AU2007235496B2 (en) * | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| ITMI20071522A1 (it) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
| PL3456190T3 (pl) | 2008-06-27 | 2022-06-06 | Merus N.V. | Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy |
| JP5827127B2 (ja) * | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US20130045492A1 (en) * | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SI2501817T2 (sl) * | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9012717B2 (en) * | 2010-06-22 | 2015-04-21 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
| SG10201912639SA (en) * | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| RU2460287C1 (ru) * | 2011-03-29 | 2012-09-10 | Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) | Трансгенная мышь, предназначенная для моделирования состояний, угрожающих развитием синдрома внезапной сердечной смерти при дистрофин-дефицитной кардиомиопатии |
| RS59728B1 (sr) * | 2011-08-05 | 2020-02-28 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lanca |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
-
2014
- 2014-03-13 WO PCT/US2014/026040 patent/WO2014160202A1/en not_active Ceased
- 2014-03-13 CA CA2903698A patent/CA2903698C/en active Active
- 2014-03-13 SI SI201432022T patent/SI3501272T1/sl unknown
- 2014-03-13 KR KR1020217027031A patent/KR102424756B1/ko active Active
- 2014-03-13 SI SI201431079T patent/SI2967013T1/sl unknown
- 2014-03-13 RS RS20230350A patent/RS64185B1/sr unknown
- 2014-03-13 ES ES14717331T patent/ES2712207T3/es active Active
- 2014-03-13 ES ES18210518T patent/ES2942413T3/es active Active
- 2014-03-13 CN CN201480013894.6A patent/CN105188357B/zh active Active
- 2014-03-13 HU HUE18210518A patent/HUE061977T2/hu unknown
- 2014-03-13 HR HRP20230490TT patent/HRP20230490T1/hr unknown
- 2014-03-13 FI FIEP18210518.9T patent/FI3501272T3/fi active
- 2014-03-13 HR HRP20190706TT patent/HRP20190706T1/hr unknown
- 2014-03-13 SG SG10201801101QA patent/SG10201801101QA/en unknown
- 2014-03-13 PT PT14717331T patent/PT2967013T/pt unknown
- 2014-03-13 HU HUE14717331A patent/HUE044003T2/hu unknown
- 2014-03-13 SM SM20190196T patent/SMT201900196T1/it unknown
- 2014-03-13 MX MX2020010837A patent/MX391010B/es unknown
- 2014-03-13 SM SM20230112T patent/SMT202300112T1/it unknown
- 2014-03-13 PT PT182105189T patent/PT3501272T/pt unknown
- 2014-03-13 AU AU2014244020A patent/AU2014244020B2/en active Active
- 2014-03-13 EP EP18210518.9A patent/EP3501272B1/en active Active
- 2014-03-13 DK DK14717331.4T patent/DK2967013T3/en active
- 2014-03-13 BR BR112015022034-7A patent/BR112015022034B1/pt active IP Right Grant
- 2014-03-13 PL PL18210518.9T patent/PL3501272T3/pl unknown
- 2014-03-13 ES ES23151398T patent/ES3013063T3/es active Active
- 2014-03-13 DK DK18210518.9T patent/DK3501272T5/da active
- 2014-03-13 EP EP23151398.7A patent/EP4218409B1/en active Active
- 2014-03-13 KR KR1020157026152A patent/KR102295842B1/ko active Active
- 2014-03-13 LT LTEP14717331.4T patent/LT2967013T/lt unknown
- 2014-03-13 RU RU2015143110A patent/RU2689664C2/ru active
- 2014-03-13 CN CN201810439928.8A patent/CN108611369B/zh active Active
- 2014-03-13 RS RS20190467A patent/RS58669B1/sr unknown
- 2014-03-13 SG SG11201506278RA patent/SG11201506278RA/en unknown
- 2014-03-13 MX MX2015012539A patent/MX357308B/es active IP Right Grant
- 2014-03-13 TR TR2019/01668T patent/TR201901668T4/tr unknown
- 2014-03-13 LT LTEP18210518.9T patent/LT3501272T/lt unknown
- 2014-03-13 PL PL14717331T patent/PL2967013T3/pl unknown
- 2014-03-13 JP JP2016502035A patent/JP6529957B2/ja active Active
- 2014-03-13 EP EP24223729.5A patent/EP4545567A3/en active Pending
- 2014-03-13 MX MX2018008279A patent/MX377146B/es unknown
- 2014-03-13 EP EP14717331.4A patent/EP2967013B1/en active Active
-
2015
- 2015-08-13 IL IL240563A patent/IL240563B/en active IP Right Grant
- 2015-08-13 ZA ZA2015/05835A patent/ZA201505835B/en unknown
-
2018
- 2018-08-13 ZA ZA2018/05369A patent/ZA201805369B/en unknown
-
2019
- 2019-01-18 JP JP2019006738A patent/JP6790136B2/ja active Active
- 2019-04-05 CY CY20191100383T patent/CY1121545T1/el unknown
- 2019-08-14 JP JP2019148806A patent/JP7010902B2/ja active Active
-
2020
- 2020-05-19 AU AU2020203238A patent/AU2020203238B2/en active Active
- 2020-07-29 JP JP2020128111A patent/JP2020182490A/ja active Pending
-
2021
- 2021-02-15 IL IL280892A patent/IL280892B2/en unknown
-
2023
- 2023-05-04 AU AU2023202783A patent/AU2023202783B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023202783B2 (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| US12389888B2 (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| US9969814B2 (en) | Methods for making fully human bispecific antibodies using a common light chain | |
| NL2014775B1 (en) | Common light chain mouse. | |
| AU2013271737A1 (en) | Methods for making fully human bispecific antibodies using a common light chain | |
| CA2865029A1 (en) | Common light chain mouse | |
| HK40097135A (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| HK40097135B (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| HK40126399A (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| HK40010381B (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| HK40010381A (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| NZ711776B2 (en) | Mice expressing a limited immunoglobulin light chain repertoire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190311 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251006 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251006 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260226 |